Loading clinical trials...
Loading clinical trials...
Open Label Study Evaluating DUOBRII in Psoriasis Patients Being Treated With Biologic Agents.
12 weeks DUOBRII to patients with 2%-10% BSA who are receiving biologic therapy for at least 24 weeks
A single center, pilot study of 25 subjects to assess 12 weeks DUOBRII to patients with 2%-10% body surface area who are receiving biologic therapy for at least 24 weeks
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Psoriasis Treatment Center of Central New Jersey
East Windsor, New Jersey, United States
Start Date
October 14, 2019
Primary Completion Date
August 1, 2020
Completion Date
September 1, 2020
Last Updated
April 30, 2020
25
ESTIMATED participants
Duobrii
DRUG
Lead Sponsor
Psoriasis Treatment Center of Central New Jersey
Collaborators
NCT07449234
NCT07116967
NCT07250802
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions